Memapsin 2, a ␤-secretase, is the membrane-anchored aspartic protease that initiates the cleavage of amyloid precursor protein leading to the production of ␤-amyloid and the onset of Alzheimer's disease. Thus memapsin 2 is a major therapeutic target for the development of inhibitor drugs for the disease. Many biochemical tools, such as the specificity and crystal structure, have been established and have led to the design of potent and relatively small transitionstate inhibitors. Although developing a clinically viable memapsin 2 inhibitor remains challenging, progress to date renders hope that memapsin 2 inhibitors may ultimately be useful for therapeutic reduction of ␤-amyloid.
Introduction
Memapsin 2 [1] , also called BACE or ASP-2 [2] [3] [4] [5] , is the protease known as ␤-secretase that initiates the pathogenesis of Alzheimer's disease (AD) [6] . In this process, a membrane protein, amyloid precursor protein (APP), is cleaved first by memapsin 2, a membrane-associated aspartic protease, and then by another protease known as ␥-secretase to generate a 40/42-residue fragment, ␤-amyloid (A␤). A␤ is neurotoxic, and its elevated level in the brain leads ultimately to neural degeneration and the onset of AD. Currently, there is no drug available for treatment of AD that can slow or stop the progression of this disease. One of the most promising therapeutic approaches, which has been shown in animal models of AD to improve cognitive functions [7, 8] , is to decrease the level of soluble A␤ in the brain. Memapsin 2 is an excellent therapeutic target for A␤ reduction strategy. Since it functions at the first step in the pathogenesis process, the inhibition of its activity would effectively eliminate the production of A␤ and all the subsequent harmful steps. Also, the removal of the memapsin 2 gene in mice produced no apparent deleterious response [9] [10] [11] , suggesting that the inhibition of memapsin 2 activity can be tolerated physiologically. Finally, the principle of inhibitor design for aspartic proteases is well known, and the successful development of inhibitor drugs against HIV protease provides an encouraging precedent. Therefore the enzymic properties of memapsin 2 are of great interest, and it has been actively studied since its identification 3 years ago.
Target properties of a memapsin 2 inhibitor drug
For the effective development of memapsin 2 inhibitor drugs, it would be useful to consider some target properties in addition to the usual low toxicity and good pharmacological properties. First, this inhibitor drug should be a transitionstate analogue of memapsin 2 catalysis. There are very few chemical reactions specific for the active sites of aspartic proteases. The esterification of catalytic aspartyls has been accomplished using EPNP [1,2-epoxy-3-(p-nitrophenoxy)-propane]-like [12] or DAN (diazoacetyl-D,L-norleucine methyl ester)-like [13] compounds, although they are not clinically viable drug candidates. On the other hand, the transition-state isostere hydroxyethylene, found originally in pepstatin A [14] , has been successfully applied in all HIV protease inhibitor drugs, suggesting that memapsin 2 inhibitor drugs should also be transition-state analogues. Secondly, to inhibit A␤ production in the brain, the inhibitor needs to penetrate the blood-brain barrier, which usually permits the passage of compounds around 500 Da or less. Within this size range, it would be difficult to incorporate into the inhibitors all desirable properties, such as potency, selectivity and pharmacological characteristics. However, some larger compounds do penetrate the blood-brain barrier. For example, the HIV protease inhibitor drug indinavir, with a molecular mass of 625 Da, can enter the brain [15] . Thus a size around 600 Da seems to be a reasonable target for the design of clinically viable memapsin 2 inhibitors. Thirdly, the potency of the inhibitor may be in the K i range of 1-10 nM. Memapsin 2 inhibitor drugs are aimed at delaying permanently the onset of the disease, so the strategy of its use in the treatment of AD will be different from that for HIV infection. For the latter, very high inhibitor potency and high dosage are necessary to completely suppress viral replication, to avoid viral resistance. Memapsin 2 inhibitor drugs will probably be used clinically to lower brain A␤ to a non-pathological level. It is known that cells expressing a Swedish mutant of APP, which manifests an early-onset form of AD, produce six to eight times the amount of A␤ as compared with cells expressing native APP [16] , thus suggesting that the inhibition of approx. 85% of memapsin 2 activity would delay the onset of AD indefinitely. The inhibition potency mentioned above will provide a near-linear dose-response within the desired inhibition range.
Biochemical tools: keys to inhibitor design
An important approach in the development of a memapsin 2 inhibitor is to utilize specificity-and structure-based design. Although this approach would require the development of many biochemical tools to elucidate memapsin 2 specificity and structure, it seems to have advantages in some respects over inhibitor lead discovery by the screening of a large chemical library. Like other aspartic proteases, memapsin 2 has a large substrate-binding site that accommodates eight residues [17] . Screening is likely to identify many compounds that interact with part of the binding cleft which typically have K i values in the micromolar range, similar to the K m of the enzyme. These 'hits' may be too numerous to be followed up. Also, without specifically screening for binding to a transition-state template, the leads may also have a long way to go to attain the desired potency. Such was the experience of the screening approach during the early development of HIV protease inhibitor drugs.
Many of the biochemical tools required for the design of memapsin 2 inhibitors have now been developed; therefore only a brief account will be given here. Production of the recombinant memapsin 2 catalytic domain by expression in Escherichia coli [1] was an important first step in supplying a sufficient amount of enzyme for subsequent studies. The kinetic assay of memapsin 2 is most conveniently performed using a fluorogenic assay [18] . Although the conversion of pro-memapsin 2 into the mature protease is effected in vivo by furin [19] [20] [21] [22] , the pro-segment on the recombinant zymogen can be removed in vitro by proteases to form a stable memapsin 2 for kinetic/inhibition assays and crystallization [18] . Crystal structures have also been determined for the catalytic unit of memapsin 2 complexed with inhibitors [23, 24] , which provide a template for inhibitor design.
Specificity of memapsin 2 and its closest homologue, memapsin 1
Like other aspartic proteases, memapsin 2 binds eight substrate residues in an extended binding cleft. To determine the complete residue preference of all eight subsites using the usual kinetic methods is very laborious, which accounted for the fact that no complete specificity had been determined prior to the memapsins. To facilitate such determinations, we devised a new approach, in which the hydrolysis of substrates in mixtures was quantified with MALDI-TOF (matrix-assisted laser-desorption ionization-time-of-flight) MS [17] . The relative rates determined are proportional to the relative k cat /K m values. The complete subsite specificity of memapsin 2 [17] is shown in Figure 1 . These data are in good agreement with those produced from the affinity binding of memapsin 2 to a partial random sequence inhibitor library [17] . The broad specificity of this protease in all eight subsites is reminiscent of the specificity of HIV-1 protease. This may be advantageous for inhibitor drug design, since it predicts the binding of many different inhibitor structures in the active site. The closest homologue of memapsin 2 is memapsin 1 [1] (BACE 2, ASP-1), which also hydrolyses APP at the ␤-secretase site [25] . We therefore also determined the complete subsite specificity of memapsin 1 [26] . Figure 1 illustrates that the two proteases share many preferred residues in subsites important for inhibitor design. For example, both proteases prefer Phe and Leu in P1, Asn and Asp in P2 and Ile, Leu and Val in P3. The subsites P1Ј to P4Ј are very non-stringent. As will be discussed below, the closeness in these two specificities posts a severe challenge for the design of selectivity in memapsin 2 inhibitors.
Binding of inhibitors in the active site of memapsin 2
Based on partial specificity information, we designed first-generation transition-state inhibitors of memapsin 2 [27] . OM99-2, which contains eight residues, EVNL*AAEF, with the scissile bond replaced by a transition-state isostere hydroxyethylene (represented as *), had high potency (K i 1.6 nM). The 1.9 Å structure of OM99-2 complexed to the catalytic unit of memapsin 2 revealed that the inhibitor is located to the substrate-binding cleft, where the inhibitor backbone interacted extensively with the active site, mostly through hydrogen bonds. Six of the eight inhibitor side chains, from P4 to P2Ј, clearly interacted with the protease [23] . The side chains of P3Ј and P4Ј, however, had high mobility and poor interaction with memapsin 2. An improved inhibitor, OM00-3 [17] , with the sequence ELDL*AVEF (K i 0.3 nM), was designed based on the specificity information and the optimized side chains. The crystal structure of the complex between memapsin 2 and OM00-3 shows that the inhibitor is essentially in an extended conformation, and all eight side chains are interacting with subsites of the protease (Figure 2) . The improved binding of subsites P3Ј and P4Ј was due mainly to improved transition-state binding of these two subsites when a valine is present in the S2Ј pocket [17] . These crystal structures provide a clear template for use in the design of a new generation of inhibitors.
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Structure-based design of a memapsin 2 inhibitor
Although the first-generation inhibitors, such as OM99-2, were quite potent, they were considerably larger than the target size. Structure-based design was carried out with aims to (a) substitute the P3Ј and P4Ј residues with a small group, since these subsites bind poorly with low stringency, (b) substitute and optimize P4 to P2 with smaller side chains, and (c) optimize the side chains of P1Ј and P2Ј. The resulting inhibitor, GT1017 [28, 29] , is considerably smaller (722 Da), yet still quite potent (K i 2.5 nM). Modelling of GT1017 in the active site of memapsin 2 revealed that the new inhibitor utilizes the main interactions between the inhibitor backbone and the protease active site. Another important consideration in the design of new inhibitors is selectivity. Among the human aspartic proteases, selectivity against memapsin 1 appears most challenging. This is illustrated by the fact that the early inhibitors designed for memapsin 2, such as OM99-2 and OM00-3, actually inhibited memapsin 1 as Figure 2 Interactions between inhibitor OM00-3 and memapsin 2.
Residues of memapsin 2 within 4.5 Å of the inhibitor are listed adjacent to the side chains of the OM00-3 structure. Underlined residues indicate those that interact with the backbone atoms of the inhibitor.
well [26] . Since the two memapsins are very similar with regard to their preferred residues in the major subsites, attempts were made to incorporate into the inhibitors less preferred residues that show the greatest difference in affinities between the two enzymes. This approach, however, did not provide the desired selectivity [26] . Improved selectivity was seen with the use of nonnative side chains, which produced inhibitors with a clear preference to inhibit memapsin 2 rather than memapsin 1. These results suggest that the structurebased design of memapsin 2 inhibitors is a powerful tool towards attaining the target inhibitor properties.
Cellular functions and transport of memapsin 2
Several lines of evidence argue that APP is not a physiological substrate of memapsin 2. First, the ultimate product of this activity, A␤, is neurotoxic, and AD is not a positive selection in evolution. Secondly, the kinetic parameters for the hydrolysis of native APP by memapsin 2 are very poor [1] . For a physiological activity, the catalytic efficiency would be likely to have improved through evolution. Thirdly, the sequence around the ␤-secretase site of APP is not well conserved, suggesting a lack of functional preservation. Thus it seems probable that cleavage of APP by memapsin 2 is a tolerable, controlled physiological error, and that the pathological process occurs only when A␤ is overproduced, as in the case of the APP Swedish mutation, or when A␤ overaccumulates in the brain by other mechanisms, as in the case of lipoprotein E4 polymorphism. These points argue for the presence of as yet unidentified physiological functions of memapsin 2. Although APP may not be a physiological substrate of memapsin 2, the localization and mechanism of APP hydrolysis may serve as a model for the physiological substrates.
The cellular functions of memapsin 2 may be intimately linked to its route of transport in the cells. Pro-memapsin 2 is biosynthesized, transported and activated to memapsin 2 through the secretory pathway via the endoplasmic reticulum and Golgi to reach the cell surface. Memapsin 2 is then endocytosed from the cell surface to endosomes, where the acidic environment, about pH 4, is optimal for its activity. Supporting the notion that the endosome is the primary site of the memapsin 2-mediated hydrolysis of APP are cellular localization studies and the inhibition of A␤ formation by bafilomycin, an inhibitor of endosomal acidification. However, ␤-secretase-mediated cleavage of APP and the formation of A␤ in the endoplasmic reticulum and Golgi have been reported by many laboratories. These compartments have pH values of between 6 and 7, a condition in which memapsin 2 has very little activity [18] . Since these studies were performed with cells overexpressing both memapsin 2 and APP Swedish , it is possible that some cleavage takes place in these compartments in the presence of high concentrations of both enzyme and substrate in spite of an unfavourable pH.
The cytosolic domain of memapsin 2 is required for its endocytosis [22, 30] . Recently, the cytosolic domain of memapsin 2, including a Leu-Leu motif and an Asp, was demonstrated to bind to the VHS ('VPS-27, Hrs and STAM') domain of GGA ('Golgi-localized, ␥-ear containing, ADP-ribosylation factor-binding') proteins [31] , which are implicated in the mechanism of memapsin 2 endocytosis. Since GGA proteins also mediate the transport of mannose-6-phosphate receptors from the trans-Golgi to endosomes, this opens up an interesting possibility that memapsin 2 may be also directly transported by this route.
Future perspectives
The biochemical tools developed for the design of structure-based inhibitors of memapsin 2 have shown considerable promise. The new generations of inhibitors are approaching the target size and potency. Although to attain clinically viable inhibitors remains challenging, the results so far provide encouragement that useful drugs against this target will eventually be possible. Little progress has been made so far on understanding of the physiological functions of memapsin 2. One may argue that the lack of phenotype caused by gene deletion would suggest that memapsin 2 inhibitor drugs can be developed without the functional knowledge. However, AD is a chronic disease, and treatment using memapsin 2 inhibitor drugs will require sustainable long-term treatment. Thus an understanding of the physiological functions of memapsin 2 and the pathological consequences of its inhibition is likely to be important in the clinical management of the disease.
